Compare DVA & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVA | RDY |
|---|---|---|
| Founded | 1994 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 11.6B |
| IPO Year | 2002 | 2001 |
| Metric | DVA | RDY |
|---|---|---|
| Price | $200.04 | $13.66 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $156.75 | $16.90 |
| AVG Volume (30 Days) | 867.0K | ★ 3.1M |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $13,643,069,000.00 | N/A |
| Revenue This Year | $3.85 | $7.72 |
| Revenue Next Year | $3.07 | $3.50 |
| P/E Ratio | $69.44 | ★ $18.67 |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $101.00 | $12.19 |
| 52 Week High | $202.69 | $16.17 |
| Indicator | DVA | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 76.16 | 54.79 |
| Support Level | $145.58 | $12.90 |
| Resistance Level | N/A | $14.06 |
| Average True Range (ATR) | 7.51 | 0.26 |
| MACD | 2.87 | 0.04 |
| Stochastic Oscillator | 96.49 | 85.84 |
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.